



MTECH

MARYLAND TECHNOLOGY ENTERPRISE INSTITUTE

Interest in UM-China Research Park

Name of Maryland Company

CytImmune Sciences Inc., Rockville, Maryland USA

Primary Company Business

Nearly one in four new therapeutic drugs entering clinical trials are monoclonal antibodies. The popularity of monoclonal antibodies is due to their specificity: they can be tailored to target specific tumors, organs and circulating molecules to fight diseases such as cancer and rheumatoid arthritis. On the downside, these antibodies currently are made in mice and therefore set off species-specific immune responses in human patients. CytImmune has successfully made a totally human monoclonal antibody in vitro (website address: <http://jazz.nist.gov/atpcf/prjbrieffs/prjbrief.cfm?ProjectNumber=00-00-6100>). Now CytImmune is making first-in-a-family of totally human therapeutic antibodies for clinical trail testing. This development effort could reduce development costs by \$600 million per antibody-based drug and reduce drug costs and side effects for consumers.

Names of Possible Chinese Companies for Collaboration

CytImmune needs to identify potential partners that are familiar with or interested in monoclonal antibody production.

Proposed Business Collaboration (Technical Area, Market Possibility, Role of Participants, etc.)

CytImmune is interested in setting up a new company with a Chinese Partner in the UM-China Research Park to commercialize this technology.